Evotec partners with Odyssey Therapeutics on AI-enabled autoimmune, inflammatory drug discovery

Reuters2026/08/06 05:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evotec entered a strategic R&D collaboration with Odyssey Therapeutics to discover new small-molecule treatments for autoimmune and inflammatory diseases.
Odyssey will use Evotec’s AI-enabled discovery platform, screening capabilities, and compound libraries to identify and validate hit series across multiple targets.
Evotec is eligible for milestone payments tied to delivery of validated hit series for each target; financial terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evotec partners with Odyssey Therapeutics on AI-enabled autoimmune, inflammatory drug discovery

You may also like

Crypto prices